PathWhiz ID | Pathway | Meta Data |
---|---|---|
PW123625View Pathway |
signaling
Metabolic pathways 1572044139Homo sapiens
|
Creator: Guest: Anonymous Created On: October 25, 2019 at 16:56 Last Updated: October 25, 2019 at 16:56 |
PW013304View Pathway |
Metabolic pathwaysMus musculus
bdnf symthesis
|
Creator: Guest: Anonymous Created On: May 02, 2017 at 07:48 Last Updated: May 02, 2017 at 07:48 |
PW064753View Pathway |
Mapa metabólicoHomo sapiens
|
Creator: Guest: Anonymous Created On: June 10, 2018 at 16:58 Last Updated: June 10, 2018 at 16:58 |
PW124286View Pathway |
Mapa metabólicohuman
mapa metabólico
|
Creator: Guest: Anonymous Created On: October 27, 2020 at 17:18 Last Updated: October 27, 2020 at 17:18 |
PW128383View Pathway |
drug action
Dosulepin Serotonin antagonist Action PathwayHomo sapiens
Dosulepin is indicated in the treatment of symptoms of depressive illness, especially where an anti-anxiety effect is required. Dosulepin displays affinity towards α2-adrenoceptors and to a lesser extent, α1-adrenoceptors. Inhibition of presynaptic α2-adrenoceptors by dosulepin facilitates noradrenaline release and further potentiates the antidepressant effects. It also downregulates central β-adrenoceptors by causing a decline in the number of receptors and reduces noradrenaline-induced cyclic AMP formation. Dosulepin binds to 5HT1A and 5HT2A receptors in the cerebral cortex and hippocampus as an antagonist. 5HT1A receptors are autoreceptors that inhibit 5HT release and 5HT2A receptors are Gi/Go-coupled receptors that reduces dopamine release upon activation. Antagonism at 5HT2A receptors may also improve sleep patterns. Dosulepin also binds to muscarinic acetylcholine receptors and causes antimuscarinic side effects such as dry mouth. By acting as an antagonist at histamine type 1 (H1) receptors, dosulepin mediates a sedative effect.
|
Creator: Omolola Created On: August 25, 2023 at 11:16 Last Updated: August 25, 2023 at 11:16 |
PW128215View Pathway |
drug action
Donepezil Action PathwayHomo sapiens
Donepezil is an acetylcholinesterase inhibitor also known as Adlarity, Aricept and Namzaric, that is used in the treatment of Alzheimer's Disease and dementia. It is administered orally or transdermally, sometimes in combination with memantine in order to treat moderate to severe dementia. Donepezil selectively inhibits the acetylcholinesterase enzyme, by doing so it is believed to enhance cholinergic transmission to relieve the symptoms of Alzheimer's and dementia. Normally acetylcholinesterase breaks down acetylcholine, this inhibited its enhances cholinergic transmission. Donepezil goes through first-pass metabolism by CYP3A4 and CYP2D6 into metabolites which can be further broken down by dealkylation, hydroxylation, oxidation, hydrolysis and glucuronidation.
|
Creator: Selena Created On: August 03, 2023 at 13:54 Last Updated: August 03, 2023 at 13:54 |
PW128196View Pathway |
drug action
Donepezil Acetylcholinesterase Inhibitor Action PathwayHomo sapiens
Donepezil is an acetylcholinesterase inhibitor that is used in the treatment of Alzheimer's Disease and dementia. It is administered orally or transdermally, sometimes in combination with memantine in order to treat moderate to severe dementia. Donepezil selectively inhibits the acetylcholinesterase enzyme, by doing so it is believed to enhance cholinergic transmission to relieve the symptoms of Alzheimer and dementia.
|
Creator: Anaya Created On: August 01, 2023 at 11:50 Last Updated: August 01, 2023 at 11:50 |
PW128386View Pathway |
drug action
Dolasetron Serotonin antagonist Action PathwayHomo sapiens
Dolasetron is a selective serotonin 5-HT3 receptor antagonist. In vivo, the drug is rapidly converted into its major active metabolite, hydrodolasetron, which seems to be largely responsible for the drug's pharmacological activity. The antiemetic activity of the drug is brought about through the inhibition of 5-HT3 receptors present both centrally (medullary chemoreceptor zone) and peripherally (GI tract). This inhibition of 5-HT3 receptors in turn inhibits the visceral afferent stimulation of the vomiting center, likely indirectly at the level of the area postrema, as well as through direct inhibition of serotonin activity within the area postrema and the chemoreceptor trigger zone.
|
Creator: Omolola Created On: August 25, 2023 at 12:02 Last Updated: August 25, 2023 at 12:02 |
PW124234View Pathway |
chebulagic acid Metabolism 1602981862Homo sapiens
|
Creator: Guest: Anonymous Created On: October 17, 2020 at 18:44 Last Updated: October 17, 2020 at 18:44 |
PW124232View Pathway |
chebulagic acid Metabolism 1602980507Homo sapiens
|
Creator: Guest: Anonymous Created On: October 17, 2020 at 18:21 Last Updated: October 17, 2020 at 18:21 |